imdusiran + peginterferon alfa-2a

Imdusiran + peginterferon alfa-2a is an investigational combination regimen being developed by Arbutus Biopharma for the treatment of chronic hepatitis B virus (cHBV) infection. The regimen combines imdusiran (AB-729), a subcutaneously administered GalNAc-conjugated small interfering RNA (siRNA) therapeutic, with pegylated interferon alfa-2a, an immunomodulatory cytokine, and ongoing nucleos(t)ide analogue (NA) therapy. Imdusiran is designed to target hepatocytes and inhibit all HBV RNA transcripts, thereby reducing viral proteins and antigens (such as HBsAg) to help reawaken the host immune response. Pegylated interferon alfa-2a acts as an immunomodulator to boost the immune response, while the nucleos(t)ide analogue therapy suppresses viral replication. The combination is currently in Phase 2 clinical development, aiming to achieve a functional cure for chronic hepatitis B.